Overview

Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-30

Target enrollment:

Participant gender:

Summary

This is a multi-dose study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.

Phase:

PHASE1

Details

Lead Sponsor:

ReCode Therapeutics